CELC Celcuity Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1603454 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-57.3%
TTM EPS YoY-28.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,192.9%
ROA-42.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets110.2%
Debt / equity—
Current ratio14.62x
Interest coverage-11.94x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-7.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $37.52M | $31.08M | $33.06M | $37.63M | $30.43M | $36.41M | $29.76M | $33.47M |
| SG&A expense | $39.80M | $35.04M | $17.44M | $11.57M | $12.42M | $7.59M | $6.37M | $2.96M |
| Operating income | -$77.32M | -$66.12M | -$50.51M | -$49.20M | -$42.85M | -$44.01M | -$36.13M | -$36.43M |
| Interest expense | $2.69M | $5.42M | $6.08M | $6.17M | $4.59M | $3.20M | $3.18M | $3.27M |
| Pretax income | -$73.34M | -$78.86M | -$52.84M | -$50.97M | -$43.80M | -$45.27M | -$37.00M | -$36.65M |
| Net income | -$73.34M | -$78.86M | -$52.84M | -$50.97M | -$43.80M | -$45.27M | -$37.00M | -$36.65M |
| EBITDA | -$77.26M | -$66.06M | -$50.46M | -$49.15M | -$42.81M | -$43.97M | -$36.10M | -$36.40M |
| EPS (basic) | -1.33 | -1.44 | -0.97 | — | -0.92 | -1.04 | -0.86 | — |
| EPS (diluted) | -1.33 | -1.44 | -0.97 | — | -0.92 | -1.04 | -0.86 | — |
| Weighted avg. shares (diluted) | 55.14M | 54.82M | 54.46M | — | 47.59M | 43.66M | 43.05M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $178.16M | $182.05M | $145.19M | $165.70M | $74.25M | $46.35M | $16.48M | $22.52M |
| Short-term investments | $464.54M | $572.00M | $241.87M | $275.79M | $380.73M | $122.03M | $189.21M | $212.59M |
| Inventory | $1.48M | — | — | — | — | — | — | — |
| Current assets | $673.96M | $775.84M | $408.93M | $465.66M | $475.50M | $183.10M | $217.60M | $244.57M |
| PP&E, net | $901,000 | $611,000 | $619,000 | $499,000 | $417,000 | $357,000 | $358,000 | $336,000 |
| Intangibles | $50.00M | $50.00M | — | — | — | — | — | — |
| Total assets | $726.87M | $828.22M | $410.16M | $466.56M | $476.00M | $183.59M | $218.13M | $245.12M |
| Current liabilities | $46.10M | $86.87M | $33.21M | $44.15M | $38.79M | $39.94M | $32.92M | $31.72M |
| Long-term debt | $0 | $0 | $137.87M | $137.55M | $137.22M | $105.59M | $105.34M | $105.09M |
| Total debt | $0 | $0 | $137.87M | $137.55M | $137.22M | $105.59M | $105.34M | $105.09M |
| Total liabilities | $800.91M | $841.00M | $356.64M | $366.00M | $359.04M | $139.22M | $131.46M | $129.50M |
| Shareholders' equity | -$74.04M | -$12.78M | $53.52M | $100.56M | $116.96M | $44.38M | $86.67M | $115.62M |
| Net debt | -$178.16M | -$182.05M | -$7.32M | -$28.16M | $62.96M | $59.24M | $88.86M | $82.58M |
| Shares outstanding | 49.12M | 48.92M | 48.35M | 48.24M | 43.27M | 38.91M | 37.84M | 37.14M |
| Cash flow statement | ||||||||
| Operating cash flow | -$66.23M | -$55.43M | -$55.06M | -$36.40M | -$44.82M | -$36.21M | -$35.85M | -$27.77M |
| Capital expenditure | $11,000 | $51,000 | $249,000 | $53,000 | $97,000 | $39,000 | $60,000 | $45,000 |
| Free cash flow | -$66.24M | -$55.48M | -$55.31M | -$36.45M | -$44.91M | -$36.25M | -$35.91M | -$27.82M |
| Investing cash flow | $60.65M | -$330.59M | $34.52M | $103.41M | -$257.61M | $65.86M | $24.26M | $37.56M |
| Financing cash flow | $1.70M | $422.87M | $34,000 | $24.44M | $330.32M | $232,000 | $5.55M | $123,000 |
| Depreciation & amortization | $61,000 | $59,000 | $47,000 | $49,000 | $41,000 | $40,000 | $37,000 | $35,000 |
| Stock-based compensation | $10.02M | $6.90M | $5.33M | $9.46M | $6.78M | $2.70M | $2.44M | $2.31M |
Free plan shows the latest 8 periods; Pro shows all 41 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.